Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Lancet

Volumn 358, Issue 9295, 2001, Pages 1754-1759

  Van Der Lely, Aart Jan ^a   Hutson, R Kent ^b   Trainer, Peter J ^c   Besser, G Michael ^d   Barkan, Ariel L ^e   Katznelson, Laurence ^f   Klibanski, Anne ^f   Herman Bonert, Vivien ^g   Melmed, Shlomo ^g   Vance, Mary Lee ^h   Freda, Pamela U ⁱ   Stewart, Paul M ^j   Friend, Keith E ^k   Clemmons, David R ^l   Johannsson, Gudmundur ^m   Stavrou, Stavros ⁿ   Cook, David M ^o   Phillips, Lawrence S ^p   Strasburger, Christian J ^q   Hacker, Suzanne ^r   Zib, Kenneth A ^s   Davis, Robert J ^s   Scarlett, John A ^s   Thorner, Michael O ^h   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TENNESSEE   (United States)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f Massachusetts General Hospital and Harvard Medical School   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ Columbia College of Physicians and Surgeons ^*  (United States)

^j QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^k UNIVERSITY OF TEXAS   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^m SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^r StatWorks Inc   (United States)

^s Sensus Drug Development Corporation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIBODY; ASPARTIC ACID; GLUCOSE; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; INSULIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TACHYPHYLAXIS; TUMOR GROWTH; TUMOR VOLUME;

EID: 0035944825     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06844-1     Document Type: Article

References (27)

1. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
3. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
4. The role of radiotherapy in acromegaly
5. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure
6. Treatment of acromegaly with dopamine agonists
7. Cabergoline in the treatment of acromegaly: A study in 64 patients
8. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly study group
9. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
10. Results of a European Multicentre study with Sandostatin LAR in acromegalic patients
11. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients
12. Rational design of potent antagonists to the human growth hormone receptor
13. The human growth hormone antagonist B2036 does not interact with the prolactin receptor
14. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
15. Treatment of acromegaly
16. The volume of pituitary macroadenomas: Assessment with MR imaging
17. Control of tumor size and disease activity during co-treatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
18. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status
19. Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
20. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
21. Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues
22. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action
23. Growth hormone and diabetes mellitus. A review of sixty-three years of medical research and a glimpse into the future?
24. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice
25. Inhibition of diabetic nephropathy by a GH antagonist: A molecular analysis
26. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin
27. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice